These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28819024)

  • 1. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
    Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
    Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
    Clifton GT; Litton JK; Arrington K; Ponniah S; Ibrahim NK; Gall V; Alatrash G; Peoples GE; Mittendorf EA
    Ann Surg Oncol; 2017 Aug; 24(8):2161-2167. PubMed ID: 28315060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine.
    Wang W; Li Y; Wang Y; Ren S; Li Y; Wang B
    Int Immunopharmacol; 2018 Jan; 54():95-102. PubMed ID: 29112895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
    Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
    J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-Induced Memory CD8
    Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
    Mittendorf EA; Gurney JM; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Surgery; 2006 Mar; 139(3):407-18. PubMed ID: 16546506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
    Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
    Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
    Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 dendritic cell vaccines.
    Morse MA; Clay TM; Colling K; Hobeika A; Grabstein K; Cheever MA; Lyerly HK
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S164-72. PubMed ID: 12620155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
    Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
    Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
    Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
    J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.